Nanomedicine offers promising opportunities for improving KRAS-mutated cancer therapy, but there are still several limitations and challenges that must be overcome related to toxicity, targeted delivery, stability, manufacturing and scale-up, and regulatory approval [49,123,124,125]. This evidence concerns the gene KRAS and cancer.